ACADIA Pharmaceuticals Inc.
HealthcareNASDAQ:ACAD · NASDAQ Global Select
-$0.30 today
Vol 0.75M · Avg 1.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
31.9%
avg -35.2%
ROIC
8.1%
avg -37.0%
ROA
25.0%
avg -30.4%
Analysis
ROE is currently the strongest return metric at 31.9% versus its period average of -35.2%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Catherine E. Owen Adams | Chief Executive Officer & Director | $1.78M | — | 56 | $14,803.00 | <0.01% |
Elizabeth Thompson | Executive Vice President and Head of Research & Development | $1.04M | — | 50 | $33,489.00 | 0.02% |
Mark C. Schneyer | Executive Vice President & Chief Financial Officer | $877,943.00 | — | 52 | $66,145.00 | 0.04% |
Jennifer J. Rhodes | Executive Vice President, Chief Legal Officer & Secretary | $857,877.00 | — | 56 | $11,280.00 | <0.01% |
Thomas Andrew Garner | Executive Vice President & Chief Commercial Officer | $857,023.00 | — | 50 | $97,947.00 | 0.06% |
Allyson McMillan Youngblood | Senior Vice President of Rare Disease Franchise | — | — | — | — | — |
Scott Cenci | Senior Vice President, Chief Information & Data Officer | — | — | — | — | — |
Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | $18,750.00 | 0.01% |
James K. Kihara | Senior Vice President of Finance | — | — | 45 | $9,311.00 | <0.01% |
Rob Ackles | Senior Vice President & Chief People Officer | — | — | — | — | — |
Konstantina Katcheves | Senior Vice President, Chief Business & Strategy Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
21
$2.76M
Net Sentiment
$2.76M
Net selling
Most Active
Schneyer Mark C.
8 transactions
1–10 of 21
Analysis
Insiders reported 0 buys worth $0.00 and 21 sells worth $2.76M over the last 12 months. That adds up to net selling of $2.76M. Schneyer Mark C. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | -76.8% | +98.6% (15yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Recent growth has been strongest in Revenue at -76.8% over three years. Forward estimates point to Revenue at +98.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
Who manages ACAD?
ACADIA Pharmaceuticals Inc. (ACAD) lists 11 active executives. The top listed executive is Allyson McMillan Youngblood, Senior Vice President of Rare Disease Franchise.
Are ACAD insiders buying or selling?
Recent insider activity shows net buying of $42.01M.
Explore More
Continue the stock analysis
Jump to another research area for this company.